Published on 06/01/2026      Lecture time : 3 minutes

 

Perfect match RCTs x NIOTECH & MEDTECH

Our more than 35 years of experience have taught us that a successful collaboration with biotech and medtech companies relies on two key pillars: flexibility and agility. RCTs supports biotech and medtech organizations in their most ambitious projects, adapting to their specific needs and providing tailored solutions.

The biotech and medtech sectors are evolving at an impressive pace. Innovations are multiplying, yet regulatory requirements and financial constraints remain major challenges.

To succeed, it is essential to rely on a strategic partner capable of combining scientific expertise, operational agility, and financial stability.
At RCTs, we understand these challenges. We know that every project is unique and deserves a personalized approach to maximize its chances of success.

 

High-level expertise from day one

From the very first interactions, the highest level of expertise is mobilized to fully understand the project’s needs and to accurately frame it. Direct access to the majority shareholder management team is always possible, ensuring continuous adjustment and adaptation of the service throughout the project.

Needs expressed by biotech and medtech companies

We get involved as early as the crucial dossier‑preparation phase, helping you navigate regulatory complexity:

Collaboration with an agile CRO

Collaboration with an agile CRO that brings expertise directly into the project

Working with a human-scale CRO

Partnering with a human-scale CRO that maintains balanced contractual relationships.

Stability and fiability

Collaboration with a reliable and financially stable CRO, whose solid shareholder structure helps secure this crucial phase of fundraising for biotech or medtech companies.

Our added value for your clinical studies

At RCTs, we don’t just carry out tasks — we become an integral part of your success.

Our support is built on three core pillars:

  • Flexibility: adapting to regulatory constraints and tight timelines.
  • Proximity: a dedicated, available, and responsive team.
  • Performance: results that meet international standards, strengthening your credibility with investors and regulatory authorities.